Compare the Best CROs for Oncology Trials

Who this guide is for

This guide is for clinical operations leads, outsourcing managers and biotech founders choosing a contract research organisation for a cancer study, from first-in-human dose escalation to registrational Phase III. If you are looking for the best CRO for oncology clinical trials, the honest answer is that it depends on your molecule, your patient population and where your sites need to be. The ranked cards above are a starting shortlist of CROs whose profiles list oncology. They tell you who to look at, not whether a CRO has recently run your tumour type, modality or country mix. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score. The criteria and RFP questions below turn the shortlist into evidence.

What an oncology CRO does — and when you need one

An oncology CRO plans and runs cancer studies on a sponsor’s behalf: feasibility, site selection, regulatory and ethics submissions, monitoring, data management, safety reporting and medical monitoring. What separates it from a generalist is depth in what cancer trials make hard: small, heavily pre-treated populations, complex dose-finding designs, tumour response assessment, biomarker-defined eligibility and high adverse-event volumes that still need careful causality assessment under ICH E2A.

Boundaries matter: central laboratories run assays, imaging core labs read scans, site management organisations supply site staff and functional service providers embed people in your teams. An oncology CRO coordinates these, and some offer them in-house.

Sub-specialty is where fit is won or lost. Precision oncology needs biomarker pre-screening and tissue logistics. Immuno-oncology needs immune-related adverse event management and handling of atypical responses. Antibody-drug conjugates bring payload-specific toxicities and complex bioanalysis. Cell and gene therapy adds apheresis scheduling and chain of identity. Radiopharmaceuticals depend on isotope supply and radiation protection approvals. Paediatric oncology means paediatric investigation plans, assent and specialist consortia. You need one when your own team cannot staff these capabilities in every country you plan to open.

How to evaluate an oncology CRO

Tumour type and modality experience

Ask for recent studies in your indication and modality, not oncology in general. A CRO comfortable with solid-tumour immunotherapy may have little cell therapy or radioligand experience. Request anonymised study summaries showing phase, design, countries and the CRO’s actual role, and meet the proposed project manager and medical monitor, not just the bid team.

Early-phase design and dose-finding

Oncology Phase I work increasingly uses model-assisted designs such as BOIN or the continual reassessment method, with expansion cohorts and the dose optimisation regulators increasingly expect. Ask who runs dose-escalation meetings, how fast cohort data are cleaned for decisions and whether the biostatisticians have built seamless Phase I/II protocols before.

Biomarker and sample operations

In precision oncology the trial lives or dies on tissue. Look for pre-screening workflows, archival and fresh biopsy handling, a clear central versus local testing strategy and turnaround tracking. If an investigational assay selects patients in Europe, ask how the CRO handles performance study obligations under IVDR 2017/746 alongside the clinical trial application.

Safety and medical monitoring

Immunotherapies, antibody-drug conjugates and cell therapies each bring distinct toxicities, from immune-related events to cytokine release syndrome, neurotoxicity and ocular or pulmonary effects. Ask about the medical monitor’s oncology background, escalation pathways, E2B(R3) expedited reporting and support for safety review committees.

Response assessment and imaging

Ask whether the CRO manages blinded independent central review, how it reconciles investigator and central reads, and how it trains sites on RECIST and iRECIST. Discordance handling should be agreed in writing before the first patient is dosed.

Site access and patient recruitment

Ask for feasibility built on current site data and competing-trial analysis. When choosing an oncology CRO UK sponsors should probe experience with the MHRA, NHS research approvals and contracting, and how quickly UK cancer centres are activated.

Regulatory pathway and quality systems

Ask how the CRO manages submissions under Regulation (EU) No 536/2014 through CTIS, combined MHRA and ethics review in the UK, and FDA interactions, including orphan, expedited and paediatric obligations. Check that quality processes follow ICH E6(R3) risk-based principles and that electronic systems meet 21 CFR Part 11.

Modality-specific logistics

For cell and gene therapy, ask about chain-of-custody controls, apheresis slot management and long-term follow-up. For radiopharmaceuticals, ask about isotope supply, dosimetry and site radiation approvals. For paediatric oncology, ask about paediatric investigation plan delivery and links with paediatric consortia.

Oncology CRO vendors at a glance

The table sets the shortlisted CROs side by side on vendor type, service model, footprint, headquarters, study phases, therapeutic areas and trial scale. Use it to separate vendors recording a global footprint from focused European options.

Reading across, most rows record a global footprint, while Smerud Medical Research and Cencora (BioPharma Excellence) are recorded as European and Tigermed as Asia / Global. Some records list every phase from Phase I to Phase IV, Worldwide Clinical Trials lists Phase I to Phase III, and others list mixed phases, so confirm phase coverage directly. None lists a UK headquarters, so UK sponsors should test local delivery in the RFP. Every field comes from each vendor’s CVC profile.

Vendor profiles

IQVIA

IQVIA is recorded as a full-service CRO with a full-service plus technology model, a global footprint and a United States headquarters, covering Phase I to Phase IV across oncology, rare disease and generalist work for large multi-region programmes. Its stated fit is complex global programmes needing broad service integration; strengths are global delivery, cross-functional service depth and data-enabled planning. Where to probe: the record notes premium pricing and possibly less agility for very small studies, so test cost and attention for a small early-phase study.

Precision for Medicine

Precision for Medicine is recorded as a specialist CRO with a global footprint and a United States headquarters, listing oncology, rare disease and complex therapies across mixed phases. Its scale is complex, biomarker-rich global development, and its cited strengths are biomarker-driven development, lab services and clinical development. Its stated fit is sponsors seeking global coverage. Where to probe: ask how lab and clinical teams share biomarker data, and confirm which phases it would cover for you.

PSI CRO

PSI CRO is recorded as a full-service CRO with a global footprint and a Swiss headquarters, covering mixed phases across oncology, cell and gene therapy, neurology and cardiology, with a specialist, private-CRO posture. Its stated fit is sponsors prioritising timeline discipline, mid-market fit and complex therapeutic depth without mega-CRO scale. Strengths cited are time-to-milestone positioning, broad therapeutic coverage and repeat-business messaging. Where to probe: the record notes public evidence is mainly corporate-site claims, so ask for comparable oncology references.

Parexel

Parexel is recorded as a full-service CRO with a global footprint and a United States headquarters, covering Phase I to Phase IV across oncology, neuroscience, rare disease and generalist work. Its stated fit is programmes with heavy regulatory complexity and global filings, and its cited strengths are regulatory depth and consultative support. Where to probe: the record flags pricing pressure for smaller biotech budgets, so ask for a scope sized to a single-asset biotech.

Worldwide Clinical Trials

Worldwide Clinical Trials is recorded as a full-service CRO with a global footprint and a United States headquarters, covering Phase I to Phase III across neuroscience, oncology, rare disease and internal medicine. Its stated fit is biotech or specialist programmes wanting high-touch support, therapeutic alignment and flexible outsourcing, with strengths in therapeutic specialisation, flexible engagement models and senior expert access. Where to probe: the record says public proof points are mostly self-described, so request oncology references.

SofPromed

SofPromed is recorded as a specialist CRO offering a full-service model, with a global footprint and a Spanish headquarters. It covers Phase I to Phase IV, listing oncology alongside cardiovascular, metabolic, CNS, dermatology, infectious disease and respiratory work. Its stated fit is sponsors needing end-to-end outsourced delivery, with strengths in breadth, delivery coverage and operational scale. Where to probe: the record suggests it suits teams seeking highly niche or ultra-boutique support less well, so confirm depth in your tumour type.

Tigermed

Tigermed is recorded as a full-service CRO with an Asia / Global footprint and a headquarters in China, covering mixed phases and listing oncology, rare disease and medical devices at large Asia / Global programme scale. Its cited strengths are clinical trial management, regulatory affairs and site management. Where to probe: if Asian sites form part of a wider oncology programme, ask how safety, data and sample export processes align with your other regions.

Smerud Medical Research

Smerud Medical Research is recorded as a full-service CRO working on a specialist model, with a European footprint and a Norwegian headquarters, covering mixed phases in oncology and rare disease for focused European studies. Its stated fit is boutique programmes needing full-service capability with clear sponsor-facing accountability, and its record cites a credible public delivery story across Europe. Where to probe: confirm which European countries and phases it covers for oncology, and how it would handle UK sites.

Cencora (BioPharma Excellence)

Cencora (BioPharma Excellence) is recorded as a specialist CRO with a European footprint and a German headquarters, covering Phase I to Phase IV in oncology and rare disease for focused European studies. Its stated fit is trials needing focused expertise or complex operational handling, with strengths in expert focus, flexibility and domain depth. Where to probe: the record suggests it is less suited to very large global programmes needing maximal scale, so test its plan if you may expand beyond Europe.

Frontage Laboratories

Frontage Laboratories is recorded as a full-service CRO operating a specialist model, with a global footprint and a United States headquarters, covering mixed phases in oncology and generalist work at mid-size to large global programme scale. Its cited strengths are clinical development and bioanalytical services. Where to probe: for biologic or antibody-drug conjugate programmes, ask whether bioanalytical and clinical teams share one project plan and how sample turnaround is reported.

Engagement and pricing models

Oncology outsourcing is usually bought as full-service, where one CRO owns delivery end to end; as functional service provision, where FSP or FTE-based teams slot into your own operation; or as a hybrid, where the CRO runs operations while you keep medical, safety or data functions. Budgets are typically unit-based, tied to sites, patients, visits and deliverables, plus pass-through costs for investigator grants, laboratories and imaging.

Oncology cost drivers are specific: screen failures in biomarker-selected studies, long treatment and survival follow-up, central imaging review, heavy safety-case volume and specialist logistics for cell therapy or radiopharmaceutical products.

Full-service simplifies accountability but reduces your control; FSP keeps control but needs a capable internal oversight team; hybrid models work only when handoffs are written into the contract. Ask every bidder to price the same assumptions and to show what triggers a change order.

Questions to put in your RFP

• Which studies in our tumour type and modality has the proposed team run, and in what role?
• How do you support dose-escalation decisions, and how quickly are cohort data cleaned for safety review meetings?
• What is your biomarker pre-screening workflow, and how do you track tissue and sample turnaround?
• How do you manage blinded independent central review and reconcile investigator and central response assessments?
• How do you escalate immune-related adverse events, cytokine release syndrome or other modality-specific toxicities?
• Which oncology sites in our target countries have you activated recently, and how will you open UK sites?
• How will you run long-term survival follow-up without inflating monitoring costs?
• Which services are in-house and which are subcontracted, such as central lab, imaging or IRT?
• How do your quality processes and systems align with ICH E6(R3) and 21 CFR Part 11?

Due-diligence red flags

• Oncology experience described only at therapeutic-area level, with no tumour-type or modality detail.
• A bid team that will not name the project manager or medical monitor.
• Feasibility drawn from historical site lists rather than current competing-trial data.
• No written plan for discordance between investigator and central imaging reads.
• Biomarker testing treated as a laboratory issue rather than an enrolment risk.
• Safety processes that cannot explain how modality-specific toxicities are escalated.
• Budgets that understate screen failures or survival follow-up and then rely on change orders.
• References that cannot be contacted, or that cover other therapeutic areas only.

Shortlist on Clinical Vendor Compare

Start in the vendor directory, filter for oncology and open the profiles that match your phase, modality and geography. Use compare to set your shortlist side by side, then send a structured RFP built around the questions above. If you have worked with one of these CROs on a cancer study, please write a review; first-hand sponsor accounts help the next team choose well.